US8703976B2 - Manufacturing process for 8-aryloctanoic acids such as Aliskiren - Google Patents

Manufacturing process for 8-aryloctanoic acids such as Aliskiren Download PDF

Info

Publication number
US8703976B2
US8703976B2 US13/337,071 US201113337071A US8703976B2 US 8703976 B2 US8703976 B2 US 8703976B2 US 201113337071 A US201113337071 A US 201113337071A US 8703976 B2 US8703976 B2 US 8703976B2
Authority
US
United States
Prior art keywords
group
formula
compound
hydrogen
chlorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US13/337,071
Other versions
US20120296100A1 (en
Inventor
Milan Soukup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/337,071 priority Critical patent/US8703976B2/en
Publication of US20120296100A1 publication Critical patent/US20120296100A1/en
Application granted granted Critical
Publication of US8703976B2 publication Critical patent/US8703976B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Definitions

  • trans-configurated (2S,7S)-2,7-diisopropyloct-4-enedioic acid (or derivatives thereof) has been used as the starting material.
  • C(5)-Amino and C(4)-hydroxy groups attached to this aliphatic C 8 -chain have been introduced via three step reaction sequence, starting with halo lactonization of trans-double bond followed by displacement of the halogen with an azide and hydrogenation of the azide group.
  • the present invention discloses a novel efficient process for manufacture of enantiomerically pure compound of general formula V and I as shown in Scheme 1:
  • the compound of formula V a known intermediate in the synthesis of compound of formula I, can be prepared by a simple sequence of steps starting from a chiral compound of formula IV.
  • the chiral compound of formula IV has been already prepared from cis- or trans-(2S,7S)-2,7-diisopropyloct-4-enedioic acid which had been obtained by double alkylation of 4(S)-benzyl-3-isovaleroyl-oxazolidin-2-one with either cis- or trans-1,4-dichloro-2-butene (U.S. Pat. No. 5,559,111 or US2011/0137047).
  • this chiral compound of formula IV reacts under Friedel-Crafts condition with inexpensive, 2-R 1 substituted anisole of formula III providing in high yield a novel compound of formula II which can be reduced and, after exchange of R 1 group for R 6 group, easily converted into compound of formula V and then of formula I.
  • the key compound of formula II can also be converted with R 7 —H into an ester or amide of formula VIII. Subsequent reduction of R 2 group into R 4 group and final replacement of R 1 group with R 6 group provides also the compound of formula I.
  • R 6 represents hydroxy, linear or brunched C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 -alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH 3 OCH 2 CH 2 CH 2 O—
  • R 4 represents NHR 8 , wherein R 8 represents hydrogen, lower alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroace
  • the chiral compound of formula IV can be prepared from either cis- or trans-(2S,7S)-2,7-diisopropyloct-4-enedioic acid via either nitro lactonization or aziridination of cis-double bond or via bromo lactonization of trans-double bond followed by displacement of halogen with an azide (U.S. Pat. No. 5,559,111 or US2011/0137047).
  • This compound of formula IV can be reacted with compound of formula III under Friedel-Crafts conditions as known to a person skilled in the art in the presence of catalyst commonly used for Friedel-Crafts reaction such as bortrifluoroetherate, HN(SO 2 CF 3 ) 2 , any metal salt, preferably Al-, Ti-, Zn-, Zr-, lanthanide-, Hf-, Bi-halide or triflate (as reported e.g. in Tetrahedron Letters 2003, 44, 2937, ibid. 2003, 44, 5343, Tetrahedron 2004, 60, 10843, ibid. 1995, 36, 409, ibid.
  • catalyst commonly used for Friedel-Crafts reaction such as bortrifluoroetherate, HN(SO 2 CF 3 ) 2 , any metal salt, preferably Al-, Ti-, Zn-, Zr-, lanthanide-, Hf-, Bi-halide or triflate (as reported e
  • aprotic organic solvent preferably chlorinated hydrocarbons as methylenechloride, dichloroethane, or aliphatic hydrocarbons, preferably hexane or heptane, or in the presence of some catalysts even aromatic hydrocarbons as toluene can be used at temperature between ⁇ 78 C until reflux, preferably at rt.
  • R 1 group is either halogen, preferably chlorine or bromine, or oxygen substituted with an electron withdrawing group such as FSO 2 O—, an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably —OMs, —OTs or —OSO 2 CF 3 .
  • Either halogen or any of these electron withdrawing groups deactivate specifically the corresponding 5-position on the aromatic ring compare to electron-rich methoxy group which selectively activates 4-position allowing thus, regioselective Friedel-Crafts reaction at this position in high yield.
  • Reduction of 8-oxo or 8-hydroxy group and 5-nitro or 5-azido groups in the compound of formula II can be achieved either simultaneously or in a few separate steps using either chemical reducing agent containing hydride as e.g.
  • silane preferably triethylsilane or tetramethyl disiloxane (TMDS) or polymeric siloxane (PMHS) in the presence of acid as trifluoroacetic or triflic acid, or various Lewis acids as aluminum or titanium chloride, or alkali or earth alkali metal hydride as LiBH 4 , NaBH 4 itself or in the presence of PTC-catalyst or transition metal salt such as Cu-, Ti- or Zr-halides, or even using hydrogen as heterogeneous or homogenous or transfer hydrogenation in the presence of transition metal such as Pt, Pd, Ra—Ni, Rh etc.
  • TMDS tetramethyl disiloxane
  • PMHS polymeric siloxane
  • the preferred reduction method for 8-oxo or 8-hydroxy group is reduction with silanes in the presence of acid, preferably triethylsilane in the presence of triflic or trifluoroacetic acid or Lewis acid as bortrifluoroetherate, ZnCl 2 , AlCl 3 or TiCl 4 , or tetramethyl disiloxane (TMDS) or polymeric siloxane (PMHS) in the presence of Lewis acid, preferably such as aluminum or titanium chloride, at reaction temperature between ⁇ 78 C until reflux, preferably at rt.
  • acid preferably triethylsilane in the presence of triflic or trifluoroacetic acid or Lewis acid as bortrifluoroetherate, ZnCl 2 , AlCl 3 or TiCl 4 , or tetramethyl disiloxane (TMDS) or polymeric siloxane (PMHS) in the presence of Lewis acid, preferably such as aluminum or titanium chloride, at reaction temperature between ⁇ 78 C
  • both step can be perform in situ in one reaction vessel as shown in Experimental section.
  • Friedel-Crafts reaction between compounds of formula III and the compound of formula IV can be carried out in methylenechloride in the presence of aluminum or titanium chloride and after completion of Friedel-Crafts reaction the reducing agent TMDS or triethylsilane can be added to accomplish reduction of 8-oxo or 8-hydroxy function (s. e.g. Heterocycles 1998, 49, 233 or Organic Process Research & Development 2008, 12, 1142) providing in one operation step directly the compound of formula VI (Scheme 2b).
  • compound of formula II wherein R 1 is an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy group, homogeneous or heterogeneous hydrogenation in the presence of common hydrogenation catalyst as know to a person skilled in the art, preferably Pt—C or Pd—C or R h , can be used. Accordingly, compound of formula II can be then reduced directly to a compound of formula VII because oxo- or hydroxy-group at C(8)-atom as well as N 3 - or NO 2 -group at C(5)-atom, when R 2 is N 3 - or NO 2 -group, are reduced simultaneously in one hydrogenation step.
  • N 3 - or NO 2 -groups are preferably reduced under other conditions than catalytic hydrogenation.
  • Na borohydride in the presence of zirconium chloride in THF can be used as reported in Syntlett 2000, 5, 683.
  • azido group preferably copper sulfate and sodium borohydride (Synthetic Commun. 1994, 24, 549) or 1,3-dithiopropane (Tetrahedron Letters 1978, 39, 3633) or trimethylsilyl iodide (Tetrahedron Letters 1997, 38, 6945) can be used.
  • R 2 is NNR 8
  • R 8 is hydrogen, lower alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably —NH 2 .HCl (ammonium hydrochloride salt), formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), preferably
  • R 1 is removed and replaced with R 6 group as defined for the compound of formula V:
  • R 6 group as defined for the compound of formula V:
  • the removal of R 1 group and replacing it by R 6 group can be carried out in one or a few separate steps, by either direct substitution of R 1 group with a nucleophilic reagent R 6 —H containing R 6 group such as hydroxy, alkoxy, alkylaryloxy, arylalkoxy, preferably CH 3 OCH 2 CH 2 CH 2 O—, without or in the presence of a catalyst such as metal or salt thereof, preferably transition metal or salts thereof such as Cu or Pd or salts and complexes thereof.
  • a catalyst such as metal or salt thereof, preferably transition metal or salts thereof such as Cu or Pd or salts and complexes thereof.
  • R 1 is halogen, preferably bromine, which can be directly substituted with alkali or earth alkali hydroxide or alcoholate, preferably alcoholate derived from CH 3 OCH 2 CH 2 CH 2 OH, such as CH 3 OCH 2 CH 2 CH 2 O ⁇ Na + , in the presence of a transition metal, preferably Cu(I) or Cu(II)-salt or Pd(0)- or Pd(II)-salt in the presence of chelating agent(s), providing the compound of formula V (s. conditions as reported in J. Chem. Soc. Chem. Commun. 1993, 419, J. Org. Chem. 2009, 74, 5075, J. Am. Chem. Soc. 2010, 132, 11592).
  • a transition metal preferably Cu(I) or Cu(II)-salt or Pd(0)- or Pd(II)-salt in the presence of chelating agent(s)
  • R 1 is alkanoyloxy- such as acetoxy, formyloxy, trifluoracetoxy, or alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy group such as CH 3 SO 2 O—, Tosyloxy-, CF 3 SO 2 O—, or FSO 2 O—
  • the cleavage of R 1 group can be carried out under basic or acidic or reductive condition as known to a person skilled in the art providing compound of formula V, wherein R 6 is phenolic hydroxy group, which can be then selectively alkylated with suitable alkylation reagent chosen according to definition of R 6 -group, preferably, alkylation of phenol or an alkali or earth alkali phenolate, with a suitable alkylating agent defined as R 6 -Lvg, wherein Lvg is a common leaving group as known to a person skilled in the art, preferably CH 3 OCH
  • the compound of formula II can be first converted into a compound of formula X by replacing R 1 -group with R 6 -group by any method as discussed above, followed then by reduction of oxo- or hydroxy-group at C(8)-atom and N 3 - or NO 2 -group at C(5)-atom leading to compound of formula V.
  • Reaction of compound of formula V with compound R 7 —H can be carried out in two different ways;
  • the compound of formula VI can be reacted with R 7 —H, similar as discussed above for conversion of compound of formula V into the final compound of formula I (Scheme 2b), providing compound of formula VIII. Subsequent replacement of R 1 -group with R 6 -group and reduction of R 2 -group into R 4 -group can be carried out in the same way as already described above.
  • all compounds can be present in the form of as enantiomerically pure compound or as racemate of one possible isomer or as a mixture of stereoisomers or mixture of racemates.
  • the invented process for enantiomerically pure compound of formulas II, IV, V, VI and VII as shown in Schemes 1 and 2 can be applied also for preparation of racemic compound which can be subjected at any stage of the synthesis to a resolution or separation step using (chiral) agent or including an enzymatic step or another separation method known as preparative HPLC or SMB etc.
  • R 6 represents linear or brunched C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 -alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH 3 OCH 2 CH 2 CH 2 O—
  • R 4 represents hydroxy or lower alkanoyloxy or an alkane-sulfonyloxy-, preferably CH 3 SO 2 O—, CF 3 SO 2 O—, or halogen, preferably chlorine, bromine, or NHR 8 , wherein R 8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably —NH 2 , benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)
  • a characteristic of protective groups is that they can be removed readily (without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, or alternatively under physiological conditions (as e.g. enzymatic cleavage or formation).
  • Different protective groups can be selected so that they can be removed selectively at different stages of the synthesis while other protective groups remain intact.
  • the corresponding alternatives can be selected readily by a person skilled in the art from those given in the standard reference works mentioned in literature (as e.g. Mc Omie “Protective Groups in Organic Chemistry” or Green et al. “Protective Groups in Organic Synthesis”) or in the description or in the claims or the Examples.
  • Acid IVe (301 g, prepared as reported in US2011/0137047) was dissolved in dry acetonitrile (600 ml) and to this solution at 0° C. under inert atmosphere and stirring DMF (5 ml) and oxalyl chloride (300 g) were slowly added. Afterwards the reaction temperature was slowly increased within ca. 30 min to 40° C. and stirred at this temperature for 4 hrs. The reaction was monitored with HPLC and TLC. After completion the solvent and excess of oxalyl chloride were evaporated under reduced pressure at a bath temperature of 30° C. providing crude chloride IVb (330 g) which was directly used in the next step in Examples 8 or 9.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a novel manufacturing process and novel intermediates useful in the synthesis of pharmaceutically active compound such as Aliskiren.
The invention describes preparation of enantiomerically pure 8-aryloctanoic acid of formula I from a chiral compound of formula IV. Friedel-Crafts reaction of this compound of formula IV with a compound of formula III provides compound of formula II which is converted reductively in a few steps into the compound of formula V, a know intermediate in the synthesis of compound of formula I. According to the disclosed process, Aliskiren can be now prepared from commercial starting materials (Guajacol or 2-bromoanisole, cis- or trans-1,4-dichloro-2-butene and 4(S)-benzyl-3-isovaleroyl-oxazolidin-2-one) in less than 8 process steps.
Figure US08703976-20140422-C00001

Description

This application claims priority to U.S. Provisional Application Ser. No. 61/542,243 filled on Oct. 2, 2011.
BACKGROUND OF THE INVENTION
8-Aryloctanoic acids of a general formula I having the 2S,4S,5S,7S-configuration,
Figure US08703976-20140422-C00002

especially compound such as Aliskiren, wherein R6 represents CH3OCH2CH2CH2O— and R7—NHCH2C(CH3)2CONH2 (IUPAC name: 5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide), are excellent antihypertensive which interfere with the rennin-angiotensin system.
After discovery of the biological activity of the compound of formula I many syntheses, especially for Aliskiren, have been reported (U.S. Pat. No. 5,559,111 and EP 0 678 503). Since Aliskiren contains 4 chiral centers, synthesis of an enantiomerically pure compound is very complex. After 2001 many patents and publications have been published claiming various alternative routes to Aliskiren and the related compounds (WO 01/09083, WO 01/09079, EP 1 215 201, WO 02/02508, WO 02/02500, WO 02/02487, WO 02/08172, WO 02/092828, WO 02/02500, WO 03/103653, UK 2 431 640, GB 2 431 641, GB 2 431 642, GB 2 431 643, GB 2 431 644, GB 2 431 645, GB 2 431 646, GB 2 431 647, GB 2 431 48, GB 2 431 649, GB 2 431 650, GB 2 431 651, GB 2 431 652, GB 2 431 653, GB 2 431 654, WO 2005/054177, WO 2005/090305, WO 2005/051895, WO 2006/131304, WO2006/095020, WO2006/024501, WO2007/054254, WO2007/039183, EP 2 062 874, EP 1958 666, WO 2007/006532, WO2007/045420, WO2008/155338, WO2008/119804, CA 2 634 513, WO2007/048620, WO2007/118681, US2009/0076062, WO2010/010165, EP2189442, WO2009/049837, EP1958666, EP2189442, WO2009/049837, US2009/0076062, WO2011/082506, WO2011/019789, WO2011/064790, WO2010/112482, WO2010/010165, US2011/0092706, US2011/0105767, US2011/0137047, Tetrahedron Letters 2000, 41, 10085, ibid. 2000, 41, 10091, ibid. 2001, 42, 4819, Drugs Fut. 2001, 1139, J. Org. Chem. 2002, 67, 4261, Helv. Chim Acta 2003, 86, 2848, Tetrahedron Letters 2005, 46, 6337, J. Org. Chem. 2006, 71, 4766, Organic Process & Develop 2007, 11, 584, Tetrahedron Letters 2008, 49, 5980 and Org. Lett. 2010, 12, 1816). Nevertheless, none of them in the event fulfills necessary requirements for a cost effective manufacturing process on technical scale.
According to a concept filled in 1994 in the original U.S. Pat. No. 5,559,111, as well as later on in other patents (WO2007/045420), trans-configurated (2S,7S)-2,7-diisopropyloct-4-enedioic acid (or derivatives thereof) has been used as the starting material. C(5)-Amino and C(4)-hydroxy groups attached to this aliphatic C8-chain have been introduced via three step reaction sequence, starting with halo lactonization of trans-double bond followed by displacement of the halogen with an azide and hydrogenation of the azide group. In an alternative approach recently published amino- and hydroxy-groups have been introduced more efficiently starting from cis-configurated (2S,7S)-2,7-diisopropyloct-4-enedioic acid by either direct nitro lactonization or aziridination of cis-double bond (US2011/0137047). Attachment of this chiral C8-aliphatic fragment to the aromatic ring has been always accomplished via addition of an appropriate organometallic reagent, preferably Grignard reagent. The disadvantage of this approach is the use of an expensive trisubstituted aromatic compound such as 4-bromo-2-R6 substituted anisole, which has been prepared from guajacol in 4 steps!, and which is required for the preparation of the organometallic reagent. As sufficiently documented in literature, preparation of organometallic reagents from aryl bromides containing electron-donating groups on the aromatic ring (as e.g. two alkoxy groups) is difficult and requires often special methods resulting in low overall yield. Consequently, synthesis of Aliskiren and related compounds is very expensive because the most expensive aliphatic C8-building block with 4 chiral centers is not used efficiently.
On the other hand, alternative coupling of 2-substituted anisole of formula III with the chiral C8-aliphatic building block of formula IV via Friedel-Crafts reaction has never been reported and such an approach represents a significant advantage against existing syntheses and it is now disclosed in the present invention.
SUMMARY OF THE INVENTION
The present invention discloses a novel efficient process for manufacture of enantiomerically pure compound of general formula V and I as shown in Scheme 1:
Figure US08703976-20140422-C00003
It has been unexpectedly found that the compound of formula V, a known intermediate in the synthesis of compound of formula I, can be prepared by a simple sequence of steps starting from a chiral compound of formula IV. The chiral compound of formula IV has been already prepared from cis- or trans-(2S,7S)-2,7-diisopropyloct-4-enedioic acid which had been obtained by double alkylation of 4(S)-benzyl-3-isovaleroyl-oxazolidin-2-one with either cis- or trans-1,4-dichloro-2-butene (U.S. Pat. No. 5,559,111 or US2011/0137047). As now disclosed this chiral compound of formula IV reacts under Friedel-Crafts condition with inexpensive, 2-R1 substituted anisole of formula III providing in high yield a novel compound of formula II which can be reduced and, after exchange of R1 group for R6 group, easily converted into compound of formula V and then of formula I. Alternatively, the key compound of formula II can also be converted with R7—H into an ester or amide of formula VIII. Subsequent reduction of R2 group into R4 group and final replacement of R1 group with R6 group provides also the compound of formula I.
DETAILED DESCRIPTION OF THE INVENTION
The present invention (Scheme 1) claims a process for preparation of a compound of formula V having the configuration as given in the formula,
Figure US08703976-20140422-C00004

wherein R6 represents hydroxy, linear or brunched C1-6 alkoxy, C1-6 alkoxy-C1-6-alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, and R4 represents NHR8, wherein R8 represents hydrogen, lower alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz) or —C(O)Otert.-butyl (BOC),
comprising following steps:
  • a) reaction of a compound of formula IV,
Figure US08703976-20140422-C00005
    • wherein R2 represents —NO2 or —N3, or NHR8, wherein R8 is hydrogen, lower alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz) or —C(O)Otert.-butyl (BOC), and
    • R3 is hydrogen or halogen, preferably chlorine or bromine, or —OC(O)R9 or —OC(O)OR9, wherein R9 is linear or brunched C1-6-alkyl, preferably methyl or tert.-butyl,
    • with a compound of formula III,
Figure US08703976-20140422-C00006
    • wherein R1 represents halogen, preferably chlorine or bromine, alkanoyloxy, preferably formyloxy or trifluoracetoxy or acetoxy, FSO2O— (fluorosulfonyloxy), an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy or CF3SO2O—,
    • under Friedel-Crafts condition in the presence of a suitable catalyst used for Friedel-Crafts reaction such as bortrifluoroetherate, HN(SO2CF3)2, metal salt, preferably Al-, Ti-, Zn-, Zr-, Bi-, lanthanide-halide or triflate, providing compound of formula II,
Figure US08703976-20140422-C00007
    • wherein R1 is the same as defined in compound of formula III,
    • R2 is as defined in compound of formula IV,
    • R5 is either void when the dotted lines are a double bond representing carbonyl, or R5 is hydrogen when the dotted lines are representing one single bond as a sec.-alcohol;
  • b) reduction of oxo- or hydroxy-group at C(8)-atom and N3- or NO2-group at C(5)-atom, when R2 is N3- or NO2-group as defined in the compound of formula II, in one or more separate steps, with a reducing agent containing either a hydride as reducing agent, preferably metal hydrides or silanes, or by homogeneous or heterogeneous hydrogenation in the presence of transition metal, preferably such as Ra—Ni, Pd, Pt or Rh,
    • followed by removal of R1-group and replacing it by R6-group as defined for the compound of formula V, accomplished in one or in a few separate steps, by
    • i) either direct substitution of R1 group with nucleophilic reagent R6—H containing R6 group such as hydroxy, alkoxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, without or in the presence of a catalyst such as metal or salt thereof, preferably transition metal or salt thereof such as Cu or Pd or salt thereof,
    • ii) or alternatively by selective cleavage of R1 group, when R1 is alkanoyloxy such as acetoxy, formyloxy, trifluoracetoxy, or FSO2O-(fluorosulfonyloxy), an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O—, Tosyloxy and CF3SO2O—, under basic or acidic or reductive condition, forming initially phenol followed by alkylation thereof with a suitable alkylation reagent R6-Lvg, wherein Lvg is a leaving group and R6 is as defined for R6 group, preferably by alkylation of phenolic group, or an alkali metal salt thereof such as phenolate, with CH3OCH2CH2CH2—X, wherein X is chlorine or bromine,
    • or vice versa by first removal of R1-group and replacing it by R6-group followed by reduction of oxo- or hydroxy-group at C(8)-atom and alternatively N3- or NO2-group at C(5)-atom.
The chiral compound of formula IV can be prepared from either cis- or trans-(2S,7S)-2,7-diisopropyloct-4-enedioic acid via either nitro lactonization or aziridination of cis-double bond or via bromo lactonization of trans-double bond followed by displacement of halogen with an azide (U.S. Pat. No. 5,559,111 or US2011/0137047). This compound of formula IV can be reacted with compound of formula III under Friedel-Crafts conditions as known to a person skilled in the art in the presence of catalyst commonly used for Friedel-Crafts reaction such as bortrifluoroetherate, HN(SO2CF3)2, any metal salt, preferably Al-, Ti-, Zn-, Zr-, lanthanide-, Hf-, Bi-halide or triflate (as reported e.g. in Tetrahedron Letters 2003, 44, 2937, ibid. 2003, 44, 5343, Tetrahedron 2004, 60, 10843, ibid. 1995, 36, 409, ibid. 2002, 43, 6331, Tetrahedron 2006, 62, 9201, Bioorg. Med. Chem. 2010, 18, 971). As solvent aprotic organic solvent, preferably chlorinated hydrocarbons as methylenechloride, dichloroethane, or aliphatic hydrocarbons, preferably hexane or heptane, or in the presence of some catalysts even aromatic hydrocarbons as toluene can be used at temperature between −78 C until reflux, preferably at rt.
In the preferred embodiment of the invention in the compound of formula III (2-substituted anisole) R1 group is either halogen, preferably chlorine or bromine, or oxygen substituted with an electron withdrawing group such as FSO2O—, an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably —OMs, —OTs or —OSO2CF3. Either halogen or any of these electron withdrawing groups deactivate specifically the corresponding 5-position on the aromatic ring compare to electron-rich methoxy group which selectively activates 4-position allowing thus, regioselective Friedel-Crafts reaction at this position in high yield.
Reduction of 8-oxo or 8-hydroxy group and 5-nitro or 5-azido groups in the compound of formula II (Scheme 2b) can be achieved either simultaneously or in a few separate steps using either chemical reducing agent containing hydride as e.g. silane, preferably triethylsilane or tetramethyl disiloxane (TMDS) or polymeric siloxane (PMHS) in the presence of acid as trifluoroacetic or triflic acid, or various Lewis acids as aluminum or titanium chloride, or alkali or earth alkali metal hydride as LiBH4, NaBH4 itself or in the presence of PTC-catalyst or transition metal salt such as Cu-, Ti- or Zr-halides, or even using hydrogen as heterogeneous or homogenous or transfer hydrogenation in the presence of transition metal such as Pt, Pd, Ra—Ni, Rh etc.
The preferred reduction method for 8-oxo or 8-hydroxy group is reduction with silanes in the presence of acid, preferably triethylsilane in the presence of triflic or trifluoroacetic acid or Lewis acid as bortrifluoroetherate, ZnCl2, AlCl3 or TiCl4, or tetramethyl disiloxane (TMDS) or polymeric siloxane (PMHS) in the presence of Lewis acid, preferably such as aluminum or titanium chloride, at reaction temperature between −78 C until reflux, preferably at rt.
Since the reaction conditions for reduction of 8-oxo or 8-hydroxy group with silanes in the presence of Lewis acids are very similar to conditions used for Friedel-Crafts reaction, both step can be perform in situ in one reaction vessel as shown in Experimental section. Preferably Friedel-Crafts reaction between compounds of formula III and the compound of formula IV can be carried out in methylenechloride in the presence of aluminum or titanium chloride and after completion of Friedel-Crafts reaction the reducing agent TMDS or triethylsilane can be added to accomplish reduction of 8-oxo or 8-hydroxy function (s. e.g. Heterocycles 1998, 49, 233 or Organic Process Research & Development 2008, 12, 1142) providing in one operation step directly the compound of formula VI (Scheme 2b).
In some cases in compound of formula II, wherein R1 is an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy group, homogeneous or heterogeneous hydrogenation in the presence of common hydrogenation catalyst as know to a person skilled in the art, preferably Pt—C or Pd—C or Rh, can be used. Accordingly, compound of formula II can be then reduced directly to a compound of formula VII because oxo- or hydroxy-group at C(8)-atom as well as N3- or NO2-group at C(5)-atom, when R2 is N3- or NO2-group, are reduced simultaneously in one hydrogenation step.
In compound of formulas II and VI, wherein R1 is halogen and R2 is either N3- or NO2-group, N3- or NO2-groups are preferably reduced under other conditions than catalytic hydrogenation. For reduction of NO2-group sodium borohydride in the presence of zirconium chloride in THF can be used as reported in Syntlett 2000, 5, 683. For reduction of azido group preferably copper sulfate and sodium borohydride (Synthetic Commun. 1994, 24, 549) or 1,3-dithiopropane (Tetrahedron Letters 1978, 39, 3633) or trimethylsilyl iodide (Tetrahedron Letters 1997, 38, 6945) can be used.
In the compound of formulas II and IV, wherein R2 is NNR8, wherein R8 is hydrogen, lower alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably —NH2.HCl (ammonium hydrochloride salt), formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), preferably R2 is, the reduction step includes only reduction of 8-oxo- or 8-hydroxy groups at C(8)-atom by anyone of methods discussed above for this step, preferably in situ after Friedel-Crafts reaction with triethylsilane or tetramethyl disiloxane in the presence of aluminum or titanium chloride at reaction temperature 0° C. to rt.
After reduction step in the compound of formula VII (Scheme 2b) protecting group R1 is removed and replaced with R6 group as defined for the compound of formula V: The removal of R1 group and replacing it by R6 group can be carried out in one or a few separate steps, by either direct substitution of R1 group with a nucleophilic reagent R6—H containing R6 group such as hydroxy, alkoxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, without or in the presence of a catalyst such as metal or salt thereof, preferably transition metal or salts thereof such as Cu or Pd or salts and complexes thereof.
In the preferred embodiment of the invention R1 is halogen, preferably bromine, which can be directly substituted with alkali or earth alkali hydroxide or alcoholate, preferably alcoholate derived from CH3OCH2CH2CH2OH, such as CH3OCH2CH2CH2ONa+, in the presence of a transition metal, preferably Cu(I) or Cu(II)-salt or Pd(0)- or Pd(II)-salt in the presence of chelating agent(s), providing the compound of formula V (s. conditions as reported in J. Chem. Soc. Chem. Commun. 1993, 419, J. Org. Chem. 2009, 74, 5075, J. Am. Chem. Soc. 2010, 132, 11592).
Alternatively, in the compound of formula VII, wherein R1 is alkanoyloxy- such as acetoxy, formyloxy, trifluoracetoxy, or alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy group such as CH3SO2O—, Tosyloxy-, CF3SO2O—, or FSO2O—, the cleavage of R1 group can be carried out under basic or acidic or reductive condition as known to a person skilled in the art providing compound of formula V, wherein R6 is phenolic hydroxy group, which can be then selectively alkylated with suitable alkylation reagent chosen according to definition of R6-group, preferably, alkylation of phenol or an alkali or earth alkali phenolate, with a suitable alkylating agent defined as R6-Lvg, wherein Lvg is a common leaving group as known to a person skilled in the art, preferably CH3OCH2CH2CH2—X, wherein X is chlorine or bromine, providing the compound of formula V (Tetrahedron Letters 2002, 43, 4281).
As further embodiment of the invention in vice versa approach (Scheme 2a), the compound of formula II can be first converted into a compound of formula X by replacing R1-group with R6-group by any method as discussed above, followed then by reduction of oxo- or hydroxy-group at C(8)-atom and N3- or NO2-group at C(5)-atom leading to compound of formula V.
Figure US08703976-20140422-C00008
Final conversion of the compound of formula V into the compound of formula I is already sufficiently reported in literature (Scheme 2b):
Reaction of compound of formula V with compound R7—H, preferably NH2CH2C(CH3)2CONH2, can be carried out in two different ways;
    • i) Comprising either initial opening of 5-membered lactone ring, protection of 4-hydroxy group and reaction of free carboxylic acid, or ester thereof, with R7—H by a method known a person skilled in the art for preparation of ester or amides
    • ii) or alternatively by direct reaction of the lactone of formula V with R7—H as reported in Novartis patent (p. 22, 23, 24, 31, 32 in U.S. Pat. No. 5,559,111). Preferably lactone of formula V can be reacted directly with NH2CH2C(CH3)2CONH2 as reported in EP-A-678 503 (p. 124, 130 and 131) or WO02/02508 (example H1 p. 35, preparation of J1) or U.S. Pat. No. 5,559,111 (example 83).
As a further embodiment of the invention the compound of formula VI can be reacted with R7—H, similar as discussed above for conversion of compound of formula V into the final compound of formula I (Scheme 2b), providing compound of formula VIII. Subsequent replacement of R1-group with R6-group and reduction of R2-group into R4-group can be carried out in the same way as already described above.
Figure US08703976-20140422-C00009
As a further embodiment of the invention depending on the number of asymmetric carbon atoms in the molecule and on choice of starting materials, all compounds can be present in the form of as enantiomerically pure compound or as racemate of one possible isomer or as a mixture of stereoisomers or mixture of racemates. The invented process for enantiomerically pure compound of formulas II, IV, V, VI and VII as shown in Schemes 1 and 2 can be applied also for preparation of racemic compound which can be subjected at any stage of the synthesis to a resolution or separation step using (chiral) agent or including an enzymatic step or another separation method known as preparative HPLC or SMB etc.
In a further embodiment of the invention the compound of formula V,
Figure US08703976-20140422-C00010

wherein R6 represents linear or brunched C1-6 alkoxy, C1-6 alkoxy-C1-6-alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, and
R4 represents hydroxy or lower alkanoyloxy or an alkane-sulfonyloxy-, preferably CH3SO2O—, CF3SO2O—, or halogen, preferably chlorine, bromine, or NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably —NH2, benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
can be prepared by
    • a) Friedel-Crafts reaction of the compound of formula IV,
Figure US08703976-20140422-C00011
    •  wherein R2 represents —NO2 or —N3, or hydroxy or lower alkanoyloxy or an alkane-sulfonyloxy-, preferably CH3SO2O—, CF3SO2O—, or halogen, preferably chlorine, bromine, or NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably —NH2, benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
    •  R3 is hydrogen or hydroxy or halogen, preferably chlorine or bromine, or —OC(O)R9 or —OC(O)OR9, wherein R9 is linear or brunched C1-6-alkyl, preferably methyl and ethyl,
    •  with a compound of formula III,
Figure US08703976-20140422-C00012
    •  wherein R1 represents halogen, preferably chlorine or bromine, alkanoyloxy, preferably acetoxy or formyloxy or trifluoracetoxy, an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy or CF3SO2O—,
    •  providing a compound of formula II,
Figure US08703976-20140422-C00013
    •  wherein R1 is the same as defined in compound of formula III,
    •  R2 is as defined in compound of formula IV,
    •  R5 is either void when the dotted lines are a double bond representing carbonyl,
    •  or R5 is hydrogen when the dotted lines are representing one single bond as sec.-alcohol;
    • b) followed by reduction of oxo- or hydroxy-group at C(8)-atom and alternatively N3- or NO2-group at C(5)-atom, when R2 is either —NO2 or —N3, in one or in a few separate steps, with a suitable reducing agent as discussed above, followed
    •  by removal of R1-group and replacing it by R6-group as defined in the compound of formula V, in one or more separate steps, by one of the methods as disclosed above,
    •  or vice versa by first removal of R1-group and replacing it by R6-group followed by reduction of oxo- or hydroxy-group at C(8)-atom and alternatively N3- or NO2-group at C(5)-atom.
In this invention a characteristic of protective groups is that they can be removed readily (without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, or alternatively under physiological conditions (as e.g. enzymatic cleavage or formation). Different protective groups can be selected so that they can be removed selectively at different stages of the synthesis while other protective groups remain intact. The corresponding alternatives can be selected readily by a person skilled in the art from those given in the standard reference works mentioned in literature (as e.g. Mc Omie “Protective Groups in Organic Chemistry” or Green et al. “Protective Groups in Organic Synthesis”) or in the description or in the claims or the Examples.
When referring to compounds described in the present invention, it is understood that references are also being made to salts thereof.
The examples are provided to illustrate particular aspects of the disclosure and do not limit the scope of the present invention as defined by the claims.
EXAMPLES
Determination of optical purity was carried out with HPLC using chiral columns as Chiralcel OJ-H, Chiralpak AS-H or Chiralpak AD-H from Daicel Chem. Ind. In some cases the optical purity was also determined with NMR-Spectroscopy using chiral Eu-shift reagent. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between 5-50 Torr in some case even under high vacuum (0.05 Torr). The structure of final products, intermediates and starting materials has been confirmed by standard analytical methods, e.g. spectroscopic characteristics as MS or NMR or IR. Abbreviation used are those conventional in the art.
Preparation of 3(S)-isopropyl-5(S)-{1(S)—BOC-amino-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-butyl}-tetrahydrofuran-2-one (Va) from 3(S)-isopropyl-5(S)-[1(S)-azido-3(S)-isopropyl-4-chloro-4-oxobutyl]-tetrahydrofuran-2-one (IVa) as shown in Scheme 3
Figure US08703976-20140422-C00014
Example 1 Preparation of IIa from IVa and IIIa
Under inert atmosphere to a stirred solution of 2-bromoanisole (300 g) in methylenechloride (1000 ml), AlCl3 (320 g) was slowly added at rt. To the resulting slurry acid chloride IVa (315 g, prepared from the corresponding acid IVc as reported in U.S. Pat. No. 5,559,111 on page 30 and 80 in example 811 or in EP2189442 example 18), dissolved in methylenechloride (600 ml), was slowly added that the reaction temperature remained below 30° C. (ice cooling!). After stirring at that temperature for 45 min the reaction mixture was heated to 40° C. for ca. 1 hr until acid chloride IVa was fully consumed. The reaction was monitored by TLC and HPLC. After completion crude reaction mixture was poured very slowly on ice (3 kg), the organic phase separated, the aqueous phase filtered and then extracted 3 times with methylenechloride (3×500 ml). The combined organic phases were washed once with water (300 ml), once with sat.-NaHCO3-solution (400 ml), then with brine (400 ml) and dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The excess of 2-bromoanisole was removed by high vacuum distillation (0.05 Torr) at ca. 80-100° C. The residue was dissolved in methylenechloride (700 ml), treated with charcoal (50 g), the solution stirred for ca. 20 min, then filtered and the filtrate concentrated under reduced pressure providing a yellow semi-crystalline IIa (430 g, 92% yield resp. to IVa). This material was directly used for the next step (IIa→VIIa):
For analytical purposes a small sample of crude IIa was purified by recrystallization from toluene/hexane: Anal. calculated for C21H28BrN3O4: C, 54.08; H, 6.05; Br, 17.13; N, 9.01; O, 13.72. Found: C, 5413; H, 6.18; Br, 16.99; N, 9.06; O, 13.80.
Example 2 Preparation of IIa from IVc and IIIa
Under inert atmosphere a mixture of HNTf2 (5 g), 2-bromoanisole (350 g), the acid IVc (30 g, prepared as reported in U.S. Pat. No. 5,559,111 on page 30 and 80 in example 81k) in toluene (400 ml) was refluxed for 36 hrs in 2 l flask equipped with Dean-Stark apparatus until acid IVc was fully consumed. The reaction was monitored by TLC and HPLC. After completion and cooling to rt the reaction mixture was poured on ice (500 g), the organic phase separated, the aqueous phase filtered and then extracted 3 times with ethyl acetate (3×100 ml). The combined organic phases were washed once with water (100 ml), once with sat.-NaHCO3-solution (50 ml), then with brine (50 ml) and dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The excess of 2-bromoanisole was removed by distillation on high vacuum (0.05 Torr) at ca. 80-100° C. The residue was dissolved in ethylacetate (100 ml), treated with charcoal (2 g), the solution stirred for ca. 20 min, then filtered and the filtrate concentrated under reduced pressure providing crystalline IIa (39 g, 84% yield). This material was directly used for the next step (IIa→VIIa): For analytical purposes a small sample of the crude IIa was purified by recrystallization from toluene/hexane.
Example 3 Preparation of VIIa from IVa and IIIa
Under inert atmosphere to a stirred solution of 2-bromoanisole (300 g) in methylenechloride (1500 ml) AlCl3 (270 g) was slowly added at 10-15° C. To the resulting slurry acid chloride IVa (315 g, prepared from the corresponding acid IVc as reported in U.S. Pat. No. 5,559,111 on pages 30 and 80 in example 811), dissolved in methylenechloride (200 ml), was slowly added over 2 hrs that the reaction temperature remained between 30-40° C. (ice cooling!). After addition the reaction mixture was heated to 35-40° C. for ca. 1-2 hrs until acid chloride IVa was fully consumed. The reaction was monitored by TLC and HPLC. After completion the reaction mixture was cooled to 0-5° C., 1,1,3,3-tetramethyldisiloxane (270 g) was slowly added and the mixture stirred at this temperature for 4-6 hrs. After completion of the reduction (monitored by TLC and HPLC) the mixture was poured very slowly on ice water (3 kg). The HCl gas that evolved during this quench was scrubbed by a caustic scrubber. The organic phase was separated and the aqueous phase filtered, extracted 3 times with methylenechloride (3×500 ml). The combined organic phases were washed once with water (300 ml), once with sat.-NaHCO3-solution (400 ml), finally with brine (400 ml), dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. Excess of 2-bromoanisole was removed by distillation on high vacuum (0.05 Torr) at ca. 80-100° C., the residue then dissolved in methylenechloride (400 ml), treated with charcoal (10 g), the solution stirred for ca. 20 min, filtered and the filtrate concentrated under reduced pressure providing yellow crystalline intermediate, 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one: 395 g (87% yield resp. to IVa). This material was directly used for the reductive step as shown in anyone of the following examples a-c):
    • a) Under inert atmosphere to a solution of crude 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one (45 g from the above Example 3) in dry acetonitrile (300 ml) sodium iodide (23 g) was added and the mixture stirred at rt for ca. 30 min. To this stirred solution TMS-Cl (16.5 g) in acetonitrile (30 ml) was added dropwise and the stirring continued for 20-60 min until the reaction was completed. The reaction conversion was monitored by HPLC and TLC. For work up the reaction mixture was quenched with 10% sodium thiosufate solution (100 ml), the product extracted from the aqueous phase 3 times with ethyl acetate (3×200 ml), the combined organic phases washed twice with brine (2×200 ml), dried with sodium sulfate (150 g), filtered, the filtrate concentrated under reduced pressure to ca. 200 ml volume. To this solution N,N-dimethylaminopyride (0.2 g), triethylamine (11 g) and di-tert-butyldicarbonate (35 g) were added at rt and the mixture stirred for 24 hrs to achieve complete BOC-protection of the amino group. After careful acidification of the reaction mixture with glacial acetic acid, the mixture was extracted with toluene/water mixture and the organic phase separated, dried and evaporated under reduced pressure providing oily VIIa: 45.1 g (86% yield)
    • b) Under inert atmosphere to a cooled (0-5° C.) and stirred mixture of copper sulphate pentahydrate (0.50 g) in methanol (100 ml) NaBH4 (1.5 g) was added. To the resulting black suspension at 0-5° C. crude 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one (45 g, prepared in the above Example 3) in dry methanol (200 ml) was then slowly added. Reaction was continued by further addition of NaBH4 (3 g) in four portions during 1-2 hrs and the stirring continued until the reaction was completed. The reaction conversion was monitored by HPLC and TLC. The reaction mixture was filtered through celite, to the filtrate glacial acetic acid (ca. 50 ml) was added, the solvents concentrated under reduced pressure to a volume of ca. 200 ml, then N,N-dimethylaminopyride (0.4 g), triethylamine (15 ml) and finally di-tert-butyldicarbonate (36 g) were added at rt and the mixture stirred for 24 hrs to achieve complete BOC-protection of amino group. After careful acidification of the reaction mixture with glacial acetic acid, the mixture was poured on water (500 ml), and the aqueous phase extracted with 3 times with ethylacetate (3×200 ml), the organic phase separated and evaporated under reduced pressure. The residue was dissolved in acetic acid (100 ml), the solution stirred for 1 hr at 35° C. until lactone formation was completed (monitored by TLC and HPLC), then acetic acid was removed under reduced pressure providing crude VIIa as crystalline material: 48.1 g (91% yield). For analytical purposes a small sample of the crude VIIa from Experiments a) or b) was purified by recrystallization from ethylacetate/hexane: Anal. calculated for C26H40BrNO5: C, 59.31; H, 7.66; Br, 15.18; N, 2.66; O, 15.9. Found: C, 59.35; H, 7.70; Br, 15.08; N, 2.60; O, 15.25.
    • c) Under inert atmosphere 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one (45 g, prepared in the above Example 3) was dissolved in freshly distilled methanol (500 ml) at rt. To this stirred solution propane-1,3-dithiol (30 g) and dry triethylamine (30 g) were added and the solution stirred at rt until the reaction was completed (ca. 2 days). The reaction conversion was monitored by HPLC and TLC. For the work up reaction mixture was evaporated under reduced pressure to dryness, the residue dissolved in aqueous conc.-HCl (1:1, ca. 200 ml), the solution stirred for ca. 1 hr at rt, and the hydrochloride salt then extracted from the aqueous phase 3 times with methylenechloride (3×200 ml), the combined organic phases washed once with brine (100 ml), dried with sodium sulfate (150 g), filtered, the filtrate concentrated under reduced pressure providing crude 3(S)-isopropyl-5(S)-{1(S)-amino-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one hydrochloride: 42 g (93% yield).
Example 4 Preparation of VIIa from IIa
Under inert atmosphere crude IIa (47 g, prepared in Example 1 or 2) was dissolved in methylenechloride (500 ml) and triethylsilane (36 g) was added at 0° C. To this solution under stirring at 0° C. TiCl4 (60 g) was slowly added that the reaction temperature was maintained at 0° C. After being stirred at rt for ca. 15 hrs the reaction was completed (monitored by TLC and HPLC). The mixture was poured slowly on ice (500 g) the organic phase separated, the aqueous phase filtered and then extracted 3 times with methylenechloride (3×100 ml). The combined organic phases were washed once with water (100 ml), once with sat.-NaHCO3-solution (100 ml), then with brine (100 ml) and dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in methylenechloride (400 ml), treated with charcoal (5 g), the solution stirred for ca. 20 min, then filtered and the filtrate concentrated in vacuum providing semi-crystalline intermediate, 3(S)-isopropyl-5(S)-{1(S)-azido-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one: 39.5 g (87% yield). This material was directly used for the reductive step as shown in Example 3 Section a) or b providing VIIa.
Example 5 Preparation of Va from VIIa
In autoclave 3-methoxy-1-propanol (300 ml) was loaded and under inert atmosphere sodium hydride (10 g), was slowly added to form the corresponding alcoholate (hydrogen evolution!). To this solution crude VIIa (53 g, prepared in Examples 3 or 4) and dry carbon dioxide (1.5 g) were added, the autoclave closed and the reaction mixture heated at 100-110° C. for 3 hrs. The reaction was completed when VIIa, as well as a lactone opening intermediate (3-methoxy-1-propyl ester of VIIa), were both consumed (monitored by TLC and HPLC after a sample was first treated with 30% aq. sodium hydroxide, extracted with ethylacetate and then acidified with acetic acid). For work up the mixture was poured on 30%-aqueous NaOH-solution (50 ml), stirred at rt for ca. 2 hrs, then acidified carefully with cold conc.-37% HCl to pH 4-5! and the aqueous phase extracted 3 times with ethylacetate (3×200 ml). The combined organic phases were washed once with brine (100 ml), dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in acetic acid (100 ml), the solution stirred for 1 hr at 30-35° C. until lactone formation was completed (monitored by TLC and HPLC), then filtered and the filtrate concentrated under reduced pressure providing an oil as Va: 40 g (75% yield).
The analytical data of Va were identical as reported in e.g. WO2006/024501 on page 58 as Example K) or WO2008/119804 on page 67 as Example 18. or in US2009/0076062 Example 26b) and c).
Example 6 Preparation of Va from VIIa
Under inert atmosphere (argon) to 3-methoxy-1-propanol (300 ml) CuI (1 g), 8-hydroxyquinoline (7 g), K3PO4 (43 g) and crude VIIa (53 g, prepared in Examples 3 or 4) were added, the apparatus 3 times evacuated and refilled with argon. The reaction mixture was heated under stirring at 110° C. for 40 hrs. The reaction was completed when VIIa, as well as a lactone opening intermediate (3-methoxy-1-propyl ester of VIIa), were both consumed (monitored by TLC and HPLC after a sample was first treated with 30% aq. sodium hydroxide, extracted with ethylacetate and then acidified with acetic acid). For work up the mixture was poured on water (1000 ml) and the aqueous phase extracted 3 times with toluene (3×300 ml). The combined organic phases were washed twice with brine (2×200 ml), dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in acetic acid (200 ml), the solution stirred for 1 hr at 35-40° C. until lactone formation was completed (monitored by TLC and HPLC), then charcoal (2 g) was added, the suspension filtered and the filtrate concentrated in vacuum providing brownish crystalline Va: 35 g (65% yield). The analytical data of Va (after purification of a small sample) were identical as reported in e.g. WO2006/024501 on page 58 as Example K) or WO2008/119804 on page 67 as Example 18. or in US2009/0076062 Example 26b) and c).
Preparation of 3(S)-isopropyl-5(S)-{1(S)—BOC-amino-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-butyl}-tetrahydrofuran-2-one (Va) from 3(S)-isopropyl-5(S)-[1(S)-nitro-3(S)-isopropyl-4-chloro-4-oxobutyl]-tetrahydrofuran-2-one (IVb) as shown in Scheme 4
Figure US08703976-20140422-C00015
Example 7 Preparation of Acid Chloride IVb
Acid IVe (301 g, prepared as reported in US2011/0137047) was dissolved in dry acetonitrile (600 ml) and to this solution at 0° C. under inert atmosphere and stirring DMF (5 ml) and oxalyl chloride (300 g) were slowly added. Afterwards the reaction temperature was slowly increased within ca. 30 min to 40° C. and stirred at this temperature for 4 hrs. The reaction was monitored with HPLC and TLC. After completion the solvent and excess of oxalyl chloride were evaporated under reduced pressure at a bath temperature of 30° C. providing crude chloride IVb (330 g) which was directly used in the next step in Examples 8 or 9.
Example 8 Preparation of IIb from IVb and IIIb
Under inert atmosphere to a stirred solution of Guajacol triflate IIIb (256 g, prepared as reported in Tetrahedron Letters 2002, 43, 7077) in methylenechloride (1000 ml) AlCl3 (280 g) was slowly added at rt. To the resulting slurry acid chloride IVb (319 g prepared in Example 7), dissolved in methylenechloride (200 ml), was slowly added that the reaction temperature remained below 30° C. (cooling!). After stirring at this temperature for 45 min the reaction mixture was heated to 40° C. for 1 hr until acid chloride IVb was consumed. The reaction was monitored by TLC and HPLC. After completion crude reaction mixture was poured slowly on ice (2.5 kg), the organic phase separated, the aqueous phase filtered and then extracted 3 times with methylenechloride (3×500 ml). The combined organic phases were washed once with water (300 ml), once with sat.-NaHCO3-solution (400 ml), then with brine (400 ml), dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in methylenechloride (300 ml), treated with charcoal (10 g), the solution stirred for ca. 20 min, then filtered and the filtrate concentrated in vacuum providing crystalline IIb (475 g, 88% yield). This material was directly used for the next step (IIb→VIIb):
For analytical purposes a small sample of the crude material was purified by recrystallization from toluene/heptane: Anal. calculated for C22H28F3NO9S: C, 48.98; H, 5.23; F, 10.56; N, 2.60; O, 26.69; S, 5.94. Found: C, 48.93; H, 5.29; F, 110.50; N, 2.55; O, 26.75; S, 5.84.
Example 9 Preparation of VIIb from IVb and IIIb
Friedel-Crafts Reaction:
Under inert atmosphere to a stirred solution of Guajacol triflate (256 g, prepared as reported in Tetrahedron Letters 2002, 43, 7077) in methylenechloride (1000 ml) AlCl3 (300 g) was slowly added at rt. To the resulting slurry acid chloride IVb (319 g, prepared from the corresponding acid IVc in Example 7), dissolved in methylenechloride (200 ml), was slowly added that the reaction temperature remained between 30-40° C. (cooling!). After stirring at that temperature for 60 min the reaction mixture was heated to 40° C. for 1-2 hrs until acid chloride IVb was fully consumed. The reaction was monitored by TLC and HPLC.
Afterwards crude reaction mixture was cooled to 0-5° C. and 1,1,3,3-tetramethyldisiloxane (270 g) was added and the mixture stirred at this temperature for 4-6 hrs. Reduction progress was monitored by TLC and HPLC. For work up the mixture was poured slowly on ice (3 kg). The HCl gas that evolved during this quench was scrubbed by a caustic scrubber. The organic phase was separated and the aqueous phase filtered, extracted 3 times with methylenechloride (3×500 ml). The combined organic phases were washed once with water (300 ml), once with sat.-NaHCO3-solution (400 ml), then with brine (400 ml), dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in ethylacetate (400 ml), treated with charcoal (10 g), the solution stirred for ca. 10 min, then filtered and the filtrate concentrated under reduced pressure providing a yellows semi-crystalline intermediate, 3(S)-isopropyl-5(S)-{1(S)-nitro-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one: 350 g (67% yield). This material was used for the reductive step:
Reduction of NO2-Group and BOC-Protection:
Under inert atmosphere ZrCl4 (23 g) and dry THF (800 ml) were placed in a flask. To this reddish brown solution, cooled 0° C., NaBH4 (15 g) was added in portions. The color of the reaction mixture turned into pale pink. To this stirred mixture at 0° C. crude 3(S)-isopropyl-5(S)-{1(S)-nitro-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one (52.5 g, prepared above in Example 9) in dry THF (200 ml) was added that the temperature was maintained at 0° C. After complete addition the reaction was allowed to reach rt and the stirring was continued until the reaction was completed (4 hrs). The reaction conversion was monitored by HPLC and TLC. For work up the reaction mixture was cooled to 0° C., filtered through celite, the filtrate quenched with aqueous 5%-HCl (200 ml) and the product extracted from the aqueous phase 3 times with methylenechloride (3×200 ml), the combined organic phases washed twice with brine (2×200 ml), dried with sodium sulfate (150 g), filtered, the filtrate concentrated under vacuum providing as crystalline 3(S)-isopropyl-5(S)-{1(S)-amino-3(S)-isopropyl-4-[4-methoxy-3-trifluoromethanesulfonyloxy-phenyl]-butyl}-tetrahydrofuran-2-one hydrochloride: 48 g (90% yield). This material was dissolved in methanol (200 ml), N,N-dimethyl aminopyride (0.2 g) triethylamine (22 g) and di-tert.-butyldicarbonate (30 g) were added at rt and the mixture stirred for 24 hrs to achieve complete BOC-protection of amino group. After careful acidification of the reaction mixture with glacial acetic acid (ca. 10 ml), the mixture was extracted with ethylacetate/water mixture, the organic phase separated and evaporated under reduced pressure providing crude VIIb as brawn crystalline material: 46 g (77% yield). A small sample was purified by column chromatography on silica gel. Anal. calculated for C27H40F3NO8S: C, 54.44; H, 6.77; F, 9.57; N, 2.35; O, 21.49; S, 5.38. Found: C, 54.50; H, 6.80; F, 9.55; N, 2.33; O, 21.40; S, 5.28.
Example 10 Preparation of VIIb from IVb and IIIb
Friedel-Crafts and reduction of 8-oxo group was carried out as described in Example 9 providing 3(S)-isopropyl-5(S)-{1(S)-nitro-3(S)-isopropyl-4-[4-methoxy-3-bromo-phenyl]-butyl}-tetrahydrofuran-2-one: 350 g (67% yield). This material was dissolved in methanol (1500 ml) and after addition of 10% Pt—C (5 g) the slurry was hydrogenated at rt under normal pressure until starting material was consumed (monitored by HPLC or TLC). The suspension was filtered through celite (20 g), to the filtrate N,N-dimethyl aminopyride (1 g), triethylamine (110 g) and di-tert.-butyldicarbonate (300 g) were added at rt and the mixture stirred for 24 hrs to achieve complete BOC-protection of the amino group. After careful acidification of the reaction mixture with glacial acetic acid (ca. 50 ml), the mixture was extracted with ethylacetate/water mixture, the organic phase separated and evaporated under reduced pressure providing crude VIIb as crystalline material: 280 g (53% yield from IVb). A small sample was purified by column chromatography on silica gel. Anal. calculated for C27H40F3NO8S: C, 54.44; H, 6.77; F, 9.57; N, 2.35; O, 21.49; S, 5.38. Found: C, 54.50; H, 6.80; F, 9.55; N, 2.33; O, 21.40; S, 5.28.
Example 11 Preparation of Va from VIIb
Under stirring at rt VIIb (60 g, prepared in Example 9) was dissolved in methanol (200 ml) and sodium methylate (5.5 g) was added. The solution was stirred for 30 min and evaporated under reduced pressure to dryness. The residue was taken into dried DMF (100 ml), 3-methoxy-propyl-1-chloride (20 g), NaJ (2 g) and potassium carbonate (7 g) were added and the suspension stirred at 80° C. for 4 hrs until the alkylation was completed. The reaction was monitored by HPLC or TLC. Glacial acetic acid (30 ml) was added, the reaction mixture poured on ice water (600 ml), the aqueous phase extracted 3 times with TBME (3×300 ml), the combined organic phases evaporated under reduced pressure. To the residue glacial acetic acid (100 ml) was added and the suspension stirred for ca. 1 hr at 50° C. for complete lactone formation (monitored by HPLC and TLC), then the solvent evaporated under reduced pressure providing crude Va as crystalline material: 49.5 g (92% yield). The analytical data of Va (after purification of a small sample by column chromatography) were identical as reported in e.g. WO2006/024501 on page 58, Example K) or in WO2008/119804 on page 67, Example 18 or in US2009/0076062, Example 26b and c).
Preparation of 3(S)-isopropyl-5(S)-{1(S)-tert.-butyloxycarbonyl-amino-3(S)-isopropyl-4-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-butyl}-tetrahydrofuran-2-one (Va) from 3(S)-isopropyl-5(S)-[1(S)-amino-3(S)-isopropyl-4-chloro-4-oxobutyl]-tetrahydrofuran-2-one hydrochloride (IVd) (Scheme 5)
Figure US08703976-20140422-C00016
Example 12 Preparation of VIId from IVc or IVe and IIIb
a) Hydrogenation of IVc or IVe:
    • IVe (301 g, prepared as reported in US2011/0137047) or IVc (297 g, prepared as reported in U.S. Pat. No. 5,559,111 on page 80, example 81k) was dissolved in glacial acetic acid (1000 ml) and after addition of conc.-37% HCl (105 ml) and 10%-Pd on charcoal (5 g) the reaction mixture was hydrogenated under vigorous stirring at rt until starting material either IVc or IVe was consumed. The hydrogenation was monitored by hydrogen consumption as well as with HPLC and TLC. The reaction suspension was then filtered through celite and the filtrate concentrated to dryness under reduced pressure proving crude amino acid hydrochloride.
b) Preparation of Acid Chloride IVd:
    • The residue from section a) was suspended into dry acetonitrile (500 ml) and to this mixture at 0° C. under inert atmosphere and stirring DMF (3 ml) and oxalyl chloride (300 g) were slowly added. Afterwards the reaction temperature was increased in ca. 30 min to 40° C. and stirred at this temperature for 4 hrs. The reaction was monitored with HPLC and TLC. After completion the solvent and excess of oxalyl chloride were evaporated under reduced pressure at a bath temperature of 30° C. providing crude chloride IVd (330 g) which was used in step c).
c) Friedel-Crafts Reaction, Reduction of 8-Oxo Group and BOC-Protection:
    • Under inert atmosphere to a stirred solution of Guajacol triflate IIIb (350 g) and acid chloride IVd (330 g, prepared in the above section b) in methylenechloride (1500 ml) TiCl4 (600 g) was slowly added at 0° C. (ice cooling!). After addition the resulting slurry was stirred between 30-40° C. for 4 hrs until acid chloride IVd was fully consumed. The reaction was monitored by TLC and HPLC. After completion of Friedel-Crafts reaction the mixture was cooled to 0-5° C. and solution of Et3SiH (350 g) in methylenechloride (500 ml) was slowly added at this temperate. After being stirred at rt over night the reduction was completed (monitored by TLC and HPLC). The mixture was poured slowly on ice water (3 kg). The organic phase was separated, the aqueous phase filtered and the filtrate extracted 3 times with methylenechloride (3×500 ml). The combined organic phases were washed once with water (300 ml), then with brine (400 ml) and dried over sodium sulfate, filtered and the filtrate concentrated under reduced pressure. The excess of qujacole triflate was removed by two extractions of the residue with toluene (2×100 ml). Afterwards the residue was dissolved in methanol (500 ml), N,N-dimethylaminopyride (1 g), triethylamine (220 g) and di-tert.-butyldicarbonate (300 g) were added at rt and the mixture stirred for 24 hrs at rt to achieve complete BOC-protection of the amino group. After careful acidification of the reaction mixture with glacial acetic acid (ca. 50 ml), the mixture was poured on water (1000 ml), the aqueous phase extracted 3 times with ethylacetate (3×300 ml) and the combined organic phases dried with sodium sulfate (300 g), filtered, the filtrate evaporated under reduced pressure providing crude VIId as semi crystalline material: 498 g (83% crude yield resp. to IVd). This material was then directly used in Example 13. For analytical purposes a small sample was purified by crystallization from acetonitrile/heptane. Anal. calculated for C27H40F3NO8S: C, 54.44; H, 6.77; F, 9.57; N, 2.35; O, 21.49; S, 5.38. Found: C, 54.34; H, 6.70; F, 9.50; N, 2.30; O, 21.55; S, 5.30.
Remarks:
      • The combination of Friedel-Crafts reaction with the reduction step can also be also accomplished in methylenechloride in the presence of AlCl3 followed by in situ reduction with 1,1,3,3-tetramethyldisiloxane similar as shown in Example 3.
Example 13 Preparation of Va from either VIId
Under stirring at rt VIId (498 g, from the experiment in Example 12) was dissolved in methanol (2000 ml) and sodium methylate (55 g) was added. The solution was stirred for 30 min at rt and then evaporated under reduced pressure to dryness. The residue was taken into acetonitrile (1000 ml), 3-methoxy-propylchloride (110 g) and NaJ (10 g) were added and the mixture stirred at 70° C. for 4 hrs until the alkylation was completed. The reaction was monitored by HPLC. Glacial acetic acid (100 ml) was added, the reaction mixture poured on water (3000 ml), the aqueous phase extracted 3 times with TBME (3×500 ml) and the solvents evaporated under reduced pressure. To the residue glacial acetic acid (500 ml) was added and the suspension stirred for ca. 1 hr at 30-40° C. for complete lactonization (monitored by HPLC and TLC), the solvent then evaporated under reduced pressure to dryness providing crude Va as crystalline brownish material: 430 g (80% yield). The analytical data of Va (after purification of a small sample) were identical as reported in e.g. WO2006/024501 on page 58 as Example K) or WO2008/119804 on page 67 as Example 18. or in US2009/0076062 Example 26b) and c).
Example 14
At rt under stirring VIId (50 g, from the experiment in Example 12) was dissolved in methanol (200 ml) and sodium hydroxide (12 g) was added. The solution was stirred for 30 min at rt, then 3-methoxy-1-propylchloride (20 g) and NaJ (1 g) were added and the solution stirred at 60° C. for ca. 5 hrs until the alkylation was completed. The reaction was monitored by HPLC. With addition of aqueous conc. 37%-HCl pH of the solution was carefully adjusted to 7, then acetic acid (ca. 50 ml) was added and the solution stirred for ca. 1 hr at 50° C. for finish the lactonisation process (monitored by HPLC and TLC). The reaction mixture was poured on water (1000 ml), the aqueous phase extracted 3 times with toluene (3×200 ml), the solvent dried with sodium sulfate (100 g), filtered, the filtrate concentrated under reduced pressure providing crude Va as brownish material: 40 g (75% yield). The analytical data of Va (after purification of a small sample by a column chromatography) were identical as reported in e.g. WO2006/024501 on page 58 as Example K) or WO2008/119804 on page 67 as Example 18. or in US2009/0076062 Example 26b) and c).

Claims (20)

The invention claimed is:
1. A compound of formula II,
Figure US08703976-20140422-C00017
wherein R1 is halogen, preferably chlorine or bromine, alkanoyloxy, preferably acetoxy or formyloxy or trifluoroacetoxy, FSO2O—, alkane-sulfonyloxy, arylalkane-sufonyloxy, arene-sulfonyloxy, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy or CF3SO2O—, and
R2 is —NO2 or —N3, or halogen, preferably chlorine, bromine, or hydroxy or lower alkoxy or lower alkanoyloxy or alkane-sulfonyloxy-, preferably CH3SO2O—, CF3SO2O—, or —NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or
R5 is hydrogen, lower alkyl, preferably methyl, alkanoyl, preferably formyl or acetyl or trifluoroacetyl or —C(O)—OMe, when the dotted lines are one single bond representing sec.-alcohol, and
a salt thereof.
2. The compound of formula II according to claim 1,
wherein R1 is chlorine, bromine, CH3SO2O—, Tosyloxy-, CF3SO2O—, and
R2 is —NO2 or —N3, or chlorine or bromine or hydroxy or lower alkanoyloxy, and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or
R5 is hydrogen, lower alkanoyl, preferably acetyl or trifluoroacetyl or —C(O)—OMe, when the dotted lines are one single bond representing sec.-alcohol or a salt thereof.
3. The compound of formula II according to claim 1,
wherein R1 is bromine, chlorine, CH3SO2O—, Tosyloxy-, CF3SO2O—, and
R2 is —N3 or chlorine or bromine or hydroxy, and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or
R5 is hydrogen, when the dotted lines are one single bond representing sec.-alcohol, and a salt thereof.
4. The compound of formula II according to claim 1,
wherein R1 is bromine, chlorine, CH3SO2O—, Tosyloxy-, CF3SO2O—, and
R2 is bromine or chlorine or —NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz) or —C(O)Otert.-butyl (BOC), and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or
R5 is hydrogen, when the dotted lines are one single bond representing sec.-alcohol, and a salt thereof.
5. The compound of formula II according to claim 1
wherein R1 is halogen, preferably chlorine or bromine, FSO2O—, an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy or CF3SO2O—, and
R2 is —NO2 or —N3, or —NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, mono-, di- or tri-methoxybenzyl, or other N-protective group, in particular one which together with N forms an amide or carbamate as —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or
R5 is hydrogen, lower alkyl, preferably methyl, lower alkanoyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)—OMe, when the dotted lines are one single bond representing sec.-alcohol or ether or ester thereof, and a salt thereof.
6. The compound of formula II according to claim 1
wherein R1 is bromine or chlorine, and
R2 is —NO2 or —N3 or —NHR8, wherein R8 is hydrogen, formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or R5 is hydrogen, when the dotted lines are one single bond representing sec.-alcohol, and a salt thereof.
7. The compound of formula II according to claim 1
wherein R1 is CH3SO2O—, Tosyloxy, CF3SO2O—, and
R2 is —NO2 or —N3 or —NHR8, wherein R8 is hydrogen, formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is either void, when the dotted lines are a double bond representing carbonyl, or R5 is hydrogen, when the dotted lines are one single bond representing sec.-alcohol, and a salt thereof.
8. The compound of formula II according to claim 1
wherein R1 is halogen, preferably chlorine or bromine, CH3SO2O—, Tosyloxy-, CF3SO2O—,
R2 is —NO2 or —N3 or —NHR8, wherein R8 is hydrogen, formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is void and the dotted lines are a double bond representing carbonyl, and a salt thereof.
9. The compound of formula II according to claim 1
wherein R1 is halogen, preferably chlorine or bromine, CH3SO2O—, Tosyloxy-, CF3SO2O—,
R2 is —NO2 or —N3 or —NHR8, wherein R8 is hydrogen, formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R5 is hydrogen and the dotted lines are one single bond representing sec.-alcohol, and a salt thereof.
10. The compound of formula II according to claim 1
wherein R1 is halogen, preferably chlorine or bromine, CH3SO2O—, Tosyloxy-, CF3SO2O—, and
R2 is —N3 and
R5 is void and the dotted lines are a double bond representing carbonyl, and a salt thereof.
11. The compound of formula II according to claim 1
wherein R1 is halogen, preferably chlorine or bromine, CH3SO2O—, Tosyloxy, CF3SO2O—, and
R2 is —NHR8, wherein R8 is hydrogen, formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
R5 is void and the dotted lines are a double bond representing carbonyl, and a salt thereof.
12. A process for preparation of the compound of formula II, having the configuration as given in the formula,
Figure US08703976-20140422-C00018
wherein R1 represents halogen, preferably chlorine or bromine, alkanoyloxy, preferably acetoxy or formyloxy or trifluoracetoxy, FSO2O—, and alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH2SO2O—, Tosyloxy-, CF3SO2O—, and
R2 is —NO2 or —N3 or —NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC), and
R5 is either void when the dotted lines are a double bond representing cabonyl, or R5 is hydrogen, when the dotted lines are one single bond, and a salt thereof,
comprising following steps:
(a) reaction of the compound of formula IV,
Figure US08703976-20140422-C00019
wherein R2 represents —NO2 or —N3, or —NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arylalkyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC), and R3 is hydrogen, hydroxy, halogen, preferably chlorine or bromine, —OC(O)R9 or —OC(O)OR9, wherein R9 is lower linear or brunched C1-6-alkyl, preferably methyl or thyl, and a salt thereof,
Figure US08703976-20140422-C00020
wherein R1 represents halogen, preferably chlorine or bromine, lower alkanoyloxy, preferably acetoxy or formyloxy or trifluoracetoxy, FSO2O— (fluorosylfonyloxy), an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy- or CF3SO2O—.
13. A process according to claim 12, wherein the compound of formula II obtained, is converted into a compound of formula V, having the configuration as given in the formula,
Figure US08703976-20140422-C00021
wherein R6 represents hydroxy, linear or brunched C1-6 alkoxy, C1-6 alkoxy-C1-6alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, and R4 represents —NHR8, wherein R8 represents hydrogen, alkyl, aryl, alkylaryl, arylalkyl, preferably benzyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-bulyl (BOC);
comprising following steps:
a. reduction of oxo- or hydroxy-group at C(8)-atom in the compound of formula II and, when R2 is N3- or NO2-group, reduction of N3- or NO2-group at C(5)-atom, in one or a few separate steps, with a reducing agent, preferably containing metal hydride or silane as reducing agent, or by homogeneous or heterogeneous hydrogenation in the presence of transition metal, preferably such as Ra—Ni, Pd, Pt or Rh,
b) followed by removal of R6-group and replacing it by R6-group as defined in the compound of formula V, in one or more separate steps, by
i) either direct substitution of R1 group with a nucleophilic reagent R8-H containing R6-group such as hydroxy, linear or brunched C1-6 alkoxy, C1-6 alkoxy—C1-6— alkoxy, aryloxy, alkylarloxy, arlyalkoxy, preferably CH3OCH2CH2CH2O—, without or in the presence of a base and a catalyst such as metal or salt thereof, preferably transition metal or salt thereof such as Cu or Pd and salt thereof,
ii) or by selective cleavage of R1 group, when R1 is lower alkanoyloxy, FSO2O—, an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O—, Tosyloxy-, CF3SO2O—, under basic or acidic or reductive condition cleaving R1 group and forming phenolic group, followed by alkylation with a suitable alkylation reagent R5Lvg, wherein Lvg is a leaving group and R6 is as defined for R6 group, preferably by alkylation of phenol or an alkali metal salt thereof (phenolate), with Ch3OCH2CH2CH2-X, wherein X is chlorine or bromine,
or vice versa by first removal of R1-group at C(8)-atom and N3- or NO2-group at C(5)-atom.
14. A process for preparation of the compound of formula V, having the configuration as given in the formula,
Figure US08703976-20140422-C00022
wherein R5 represents hydroxy, linear or brunched C1-6 alkoxy, C1-6 alkoxy-C1-6-alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O—, and R4 represents —NHR5, wherein R5 represents hydrogen, alkyl, aryl, alklaryl, arylalkyl, preferably benzyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)aryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
comprising following steps:
a) reaction of the compound of formula IV,
Figure US08703976-20140422-C00023
wherein R2 represents —NO2 or —N3, or NHR8, wherein R8 is hydrogen, alkyl, aryl, alkylaryl, arulalkyl, preferably benzyl, —C(O)alkyl, —C(O)aryl, —C(O)alkylaryl, —C(O)arylalkyl, —C(O)Oalkyl, —C(O)Oaryl, —(O)COalkylaryl, —C(O)Oarylalkyl, preferably formyl, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC), and R8 is hydrogen or hydroxy or halogen, preferably chlorine, bromine, or —OC(O)R9 or —OC(O)OR9, wherein R9 is lower linear or brunched C1-6-alkyl, preferably methyl or ethyl or tert.-butyl, and a salt thereof,
with a compound of formula III,
Figure US08703976-20140422-C00024
wherein R1 represents halogen, preferably chlorine or bromine, alkanoyloxy, preferably acetoxy, formyloxy, triflouracetoxy, FSO2O— (fluorosulfonyloxy), an alkane-, arylalkane-, alkylarene-, arene-sulfonyloxy, preferably CH3SO2O— or Tosyloxy- or CF3SO2O—,
under Friedel-Crafts condition in the presence of a suitable catalyst used for Friedel-Crafts reaction such as bortrifluoroetherate, HN(SO2CF3)2, metal salt, preferably Al-, Ri-, Zn-, Zr-, Bi-, lanthanide-halide or triflate, providing compound formula II,
Figure US08703976-20140422-C00025
wherein R1 is the same as defined in compound of formula III, R2 is as defined in compound of formula IV,
R5 is either void when the dotted lines are a double bond representing carbonyl, or R5 is hydrogen, when the dotted lines are one single bond representing a sec.-alcohol:
b) reduction of oxo- or hydroxy-group at C(8)-atom and N3— or NO2—group at C(5)-atom, where R2 is N3— or NO2—group as defined in the compound of formula II, in one or in a few separate steps, with a reducing agent, preferably containing metal hydride or silane as reducing agent, or by homogeneous or heterogeneous hydrogenalion in the presence of transition metal, preferably such as Ra-Ni, Pd, Pt or Rh,
followed by removal of R3-group and replacing it by R6-group as defined in the compound of formula V, in one or more separate steps, by
i) either direct substitution of R1 group with a nucleophilic reagent R6-H containing R6-group such as hydroxy, linear or brunched C1-6 alkoxy, C1-6 alkoxy-C1-6- alkoxy, aryloxy, alkylaryloxy, arylalkoxy, preferably CH3OCH2CH2CH2O, without or in the presence of a catalyst such as metal or salt thereof, preferably transition metal or salt thereof such as Cu or Pd and salt thereof,
ii) or by selective cleavage of R3 group, when R1 is alkanoyloxy, an alkane-, arylalkane-, alkylarene-, arene- sulfonyloxy, preferably CH3SO2O—, Tosyloxy-, CF3SO2O—, under basic or acidic or reductive condition cleaving R1 group and forming phenolic group followed by alkylation thereof with a suitable alkylation reagent defined as R6-Lvg, wherein Lvg is a leaving group and R6 is group defined, preferably by alkylation of phenolic group, or an alkali metal salt thereof such as phenolate, with CH3OCH2CH2CH2-X, wherein X is chlorine or bromine,
or vice versa by first removal of R1group and replacing it by R6-group followed by reduction of oxo- or hydroxy-group at C(8)-atom and N3— or NO2—group at C(5)-atom.
15. A process according to anyone of claims 12-14, wherein in the compounds of formulas II, III, IV, V and VI
R1 represents chlorine or bromine,
R2 represents N3,
R3 represents chlorine,
R4 represents NHR8, wherein R8 is hydrogen, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
R5 is void and the dotted lines are a double bond representing carbonyl, and
R6 is CH3OCH2CH2CH2O—, and
R1 group in compound of formula VII was replaced by direct substitution of R3 group with CH3OCH2CH2CH2O— group by treatment with CH3OCH2CH2CH2OH in the presence of a base and catalyst such as Cu- or Pd-salt.
16. A process according to anyone of claims 12-14, wherein in the compounds of formulas II, III, IV, V and VII
R1 represents chlorine or bromine,
R2 represents —NH3 +Cl or NHR8 is acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R3 represents chlorine,
R4 represents NHR8, wherein R8 represents hydrogen, acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC),
R5 is void and the dotted lines are a double bone representing carbonyl, and
R6 is CH3OCH2CH2CH2O— and
R1 group in compound of formula VII was replaced by direct substitution of R1 group with CH2OCH2CH2CH2O by treatment with CH2OCH2CH2CH2OH in the presence of a base and catalyst such as Cu- or Pd- salt.
17. A process according to anyone of claim 12-14, wherein in the compounds of formulas II, III, IV, V and VII
R1 represents CH3SO2O—, Tosyloxy-, CF3SO2O—,
R2 represents NH3 +Cl or NHR8, wherein R8 is acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC), and
R3 represents chlorine,
R4 represents NHR8, wherein R8 represents hydrogen, acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC),
R5 is void and the dotted lines are a double bond representing crabonyl, and
R8 is CH3OCH2CH2CH2O—, and
R1 group in the compound of formula VII was removed by selective cleavage of R1 group under basic condition forming phenolic group, followed by alkylation of alkali metal phenolate with CH3OCH2CH2CH2—X, wherein X is chlorine or bromine.
18. A process according to anyone of claims 12-14, wherein in the compounds of formulas II, III, IV, V and VII
R1 represents chlorine or bromine,
R2 represents N3 or NO2 or —NH2 +Cl or NHR8, wherein R8 is acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC),
R3 represents chlorine,
R4 represents NHR8 , wherein R8 represents hydrogen, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
R5 is hydrogen and the dotted lines are one single bond representing sec.-alcohol, and
R6 is CH3OCH2CH2CH2O—, and
R1 group in compound of formula II was replaced by direct substitution of R1 group with CH3OCH2CH2CH2O— by treatment with CH3OCH2CH2CH2OH in the presence of a base and catalyst such as Cu or Pd-salt.
19. A process according to anyone of claims 12-14, wherein in the compounds of formulas II, III, IV, V and VII
R1 represents CH3SO2O—, Tosyloxy or CF3SO2O—,
R2 represents N3,
R3 represents chlorine,
R4 represents NHR8, wherein R8 represents hydrogen, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
R5 is void and the dotted lines are a double bond representing carbonyl, and
R6 is CH3OCH2CH2CH2O—, and
R1 group in the compound of formula VII was removed by selective cleavage of R1 group under basic condition forming phenolic group, followed by alkylation of alkali metal phenolate with CH3OCH2CH2CH2—X, wherein X is chlorine or bromine.
20. A process according to anyone of claim 12-14, wherein in the compounds of formulas II, III, IV, V and VII
R1 represents CH3SO2O—, Tosyloxy and CF3SO2O—,
R2 represents N3 or NO2 or NH3 +Cl or NHR8, wherein R8 is acetyl, trifluoroacetyl, —C(O)OMe, —C(O)Obenzyl (Cbz), —C(O)Otert-butyl (BOC),
R3 represents chlorine,
R4 represents NHR8, wherein R8 represents hydrogen, acetyl, trifluoroacetyl, —C(O)Obenzyl (Cbz), —C(O)Otert.-butyl (BOC),
R5 is hydrogen and the dotted lines are one single bond representing a sec.-alcohol, and
R6 is CH3OCH2CH2CH2O—, and
R1 group in the compound of formula VII was removed by selective cleavage of R1 group under basic condition forming phenolic group, followed by alkylation of alkali metal phenolate with CH3OCH2CH2CH2—X, wherein X is chlorine or bromine.
US13/337,071 2011-10-02 2011-12-24 Manufacturing process for 8-aryloctanoic acids such as Aliskiren Expired - Fee Related US8703976B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/337,071 US8703976B2 (en) 2011-10-02 2011-12-24 Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542243P 2011-10-02 2011-10-02
US13/337,071 US8703976B2 (en) 2011-10-02 2011-12-24 Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Publications (2)

Publication Number Publication Date
US20120296100A1 US20120296100A1 (en) 2012-11-22
US8703976B2 true US8703976B2 (en) 2014-04-22

Family

ID=47175414

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/337,071 Expired - Fee Related US8703976B2 (en) 2011-10-02 2011-12-24 Manufacturing process for 8-aryloctanoic acids such as Aliskiren

Country Status (1)

Country Link
US (1) US8703976B2 (en)

Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559111A (en) * 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
WO2001009083A1 (en) 1999-07-29 2001-02-08 Speedel Pharma Ag Production of n-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides
WO2002002508A1 (en) 2000-07-05 2002-01-10 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
WO2002002487A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
WO2002002500A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Preparation of (r)-2-alkyl-3-phenylpropionic acids
WO2002008172A1 (en) 2000-07-25 2002-01-31 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
WO2002092828A2 (en) 2001-05-15 2002-11-21 Speedel Pharma Ag Process for the preparation of substituted carboxylic acid estersby enzymatic hydrolysis
WO2003103653A1 (en) 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
WO2005090305A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
WO2006024501A1 (en) 2004-08-31 2006-03-09 Novartis Ag Alternative synthesis of renin inhibitors and intermediates thereof
WO2006095020A1 (en) 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
EP1215201B1 (en) 2000-12-14 2006-10-18 Speedel Pharma AG Process for the preparation of aryloctanoyl amides
WO2006131304A2 (en) 2005-06-08 2006-12-14 Novartis Ag Process for preparing renin inhibitors
WO2007006532A1 (en) 2005-07-11 2007-01-18 Novartis Ag New pyrocatechin derivatives
WO2007039183A1 (en) 2005-09-28 2007-04-12 Novartis Ag Sythesis of renin inhibitors involving a cycloaddition reaction
WO2007045420A2 (en) 2005-10-17 2007-04-26 Novartis Ag 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
GB2431653A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431643A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431642A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431644A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431646A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431650A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431647A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431651A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431640A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431652A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431641A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431654A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
WO2007048620A1 (en) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Process for preparing octenoic acid derivatives
WO2007054254A1 (en) 2005-11-08 2007-05-18 Novartis Ag Organic compounds
WO2007118681A1 (en) 2006-04-12 2007-10-25 Reuter Chemischer Apparatebau Kg Method for the production of 8-aryl-octanoyl derivatives
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008119804A1 (en) 2007-04-03 2008-10-09 Novartis Ag New methods
WO2008155338A2 (en) 2007-06-19 2008-12-24 Novartis Ag Organic compounds
WO2009049837A1 (en) 2007-10-11 2009-04-23 Reuter Chemischer Apparatebau Kg Process for preparing 8-hydrazino-8-aryloctanoyl derivatives and their use
EP2062874A1 (en) 2007-11-20 2009-05-27 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CA2634513A1 (en) 2008-06-09 2009-12-09 Stephen Hanessian Novel intermediate compounds and processes for their preparation
WO2010010165A1 (en) 2008-07-23 2010-01-28 Dsm Ip Assets Bv Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
EP2189442A1 (en) 2008-11-20 2010-05-26 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
WO2010112482A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
US20110092706A1 (en) 2009-10-21 2011-04-21 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
US20110105767A1 (en) 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011064790A1 (en) 2009-11-30 2011-06-03 Avra Laboratories Pvt. Ltd A novel process for making aliskiren, its novel intermediates and certain novel compounds
US20110137047A1 (en) 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011082506A1 (en) 2010-01-06 2011-07-14 浙江天宇药业有限公司 Method for preparing aliskiren and intermediate thereof
WO2011082806A2 (en) 2010-01-05 2011-07-14 Steinbeis-Transferzentrum Angewandte Photovoltaik Und Dünnschichttechnik Solar cell module

Patent Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0678503B1 (en) 1994-04-18 1999-09-01 Novartis AG Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities
US5559111A (en) * 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
WO2001009083A1 (en) 1999-07-29 2001-02-08 Speedel Pharma Ag Production of n-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides
WO2001009079A1 (en) 1999-07-29 2001-02-08 Speedel Pharma Ag 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
WO2002002487A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
WO2002002500A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Preparation of (r)-2-alkyl-3-phenylpropionic acids
WO2002002508A1 (en) 2000-07-05 2002-01-10 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
WO2002008172A1 (en) 2000-07-25 2002-01-31 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
EP1215201B1 (en) 2000-12-14 2006-10-18 Speedel Pharma AG Process for the preparation of aryloctanoyl amides
WO2002092828A2 (en) 2001-05-15 2002-11-21 Speedel Pharma Ag Process for the preparation of substituted carboxylic acid estersby enzymatic hydrolysis
WO2003103653A1 (en) 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
WO2005090305A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
WO2006024501A1 (en) 2004-08-31 2006-03-09 Novartis Ag Alternative synthesis of renin inhibitors and intermediates thereof
WO2006095020A1 (en) 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
WO2006131304A2 (en) 2005-06-08 2006-12-14 Novartis Ag Process for preparing renin inhibitors
WO2007006532A1 (en) 2005-07-11 2007-01-18 Novartis Ag New pyrocatechin derivatives
WO2007039183A1 (en) 2005-09-28 2007-04-12 Novartis Ag Sythesis of renin inhibitors involving a cycloaddition reaction
WO2007045420A2 (en) 2005-10-17 2007-04-26 Novartis Ag 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
GB2431651A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431645A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431643A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431642A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431644A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431646A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431650A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431647A (en) 2005-10-25 2007-05-02 Novartis Ag Synthesis of aryl-octanoyl amide compounds
GB2431653A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431640A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431652A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431641A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431654A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
WO2007048620A1 (en) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Process for preparing octenoic acid derivatives
WO2007054254A1 (en) 2005-11-08 2007-05-18 Novartis Ag Organic compounds
WO2007118681A1 (en) 2006-04-12 2007-10-25 Reuter Chemischer Apparatebau Kg Method for the production of 8-aryl-octanoyl derivatives
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008119804A1 (en) 2007-04-03 2008-10-09 Novartis Ag New methods
WO2008155338A2 (en) 2007-06-19 2008-12-24 Novartis Ag Organic compounds
WO2009049837A1 (en) 2007-10-11 2009-04-23 Reuter Chemischer Apparatebau Kg Process for preparing 8-hydrazino-8-aryloctanoyl derivatives and their use
EP2062874A1 (en) 2007-11-20 2009-05-27 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CA2634513A1 (en) 2008-06-09 2009-12-09 Stephen Hanessian Novel intermediate compounds and processes for their preparation
WO2010010165A1 (en) 2008-07-23 2010-01-28 Dsm Ip Assets Bv Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
EP2189442A1 (en) 2008-11-20 2010-05-26 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
WO2010112482A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
US20110092706A1 (en) 2009-10-21 2011-04-21 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
US20110105767A1 (en) 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011064790A1 (en) 2009-11-30 2011-06-03 Avra Laboratories Pvt. Ltd A novel process for making aliskiren, its novel intermediates and certain novel compounds
US20110137047A1 (en) 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011082806A2 (en) 2010-01-05 2011-07-14 Steinbeis-Transferzentrum Angewandte Photovoltaik Und Dünnschichttechnik Solar cell module
WO2011082506A1 (en) 2010-01-06 2011-07-14 浙江天宇药业有限公司 Method for preparing aliskiren and intermediate thereof

Non-Patent Citations (80)

* Cited by examiner, † Cited by third party
Title
A. Andrusko et a. Tetrahedron letters 2008, 49, 5980.
A. Dondoni et al. Terahedron Letters, 2001, 42, 4819.
A. Inoue et al.J. Org. Chem. 2001, 66, 4333.
A. On et al. Synthesis, 1987, 736.
A.J. Bloom et al. Tetrahedron Letters 1986, 27, 873.
A.Kamal et al. Terahedron Lett. 1997, 39, 6945.
C. Berse et al. Can. J. Chem. 1971, 49, 2610.
Ch.T. West et al., J. Org. Chem. 1973, 38, 2675.
D. Billeret et al. J. Heterocycl. Chem. 1993, 30, 671.
D.A. Sandham et al. Tetrahedron Letters, 2000, 41, 10091.
D.J. Ager etal. Org. Process Res. & Develop. 2004, 8, 72.
D.Nobel Chem Commun. 1993, 419.
D.V. Nadkarni et al. Org. Proc.Res.&Develop. 2008, 12, 1142.
Drugs future, 2001, 26(12).
E,J; Corey et al. Tetrahedron letters 1980, 21, 1819.
E. Vedejs et al. J. Am. Chem. Soc. 1996, 1809.
E.Gross The Peptides, vol. 1 and 2, Academic Press. London 1970/80.
F. Pesciaioli et al. Angew. Chem. Int. 2008, 47, 8703.
G. Olah, et al. Synthesis, 1986, 770.
G.A.Klau et al. Terahedron Lett. 2002, 43, 7077.
G.A.Kraus et al. Tetrahedron letters 2002, 43, 7077.
H. Aray et al. Tetrahedron Lett. 2009, 50, 3329.
H. Bayley et al. Tetrahedron Lett. 1978, 39, 3633.
H. Fillon et al. Tetrahedron 2003, 59, 8199.
H. Firouzabadi et al. Tetrahedron 2004, 60, 10843.
H. Nozaki Can. J. Chem. 1968, 46, 3333.
H. Ruger et al. Tetrahedron Letters, 2000, 41, 100085.
H. Sheldrake et al. Org. Biomol. Chem. 2009, 7, 205.
H.S.Prakash et al. Syn Commun. 1994, 24, 549.
Hoben-Weyl, Methoden der Org. Chemie, 4th Ed., Synthese von Peptidenl , vol. 15/II (1974), vol. IX (1955), vol. E11 (1985), Thieme Verlag.
Hua Dong et al. Tetrahedron Letters 2005, 46, 6337.
J. Advanced Org. Chem. J Wiley&sons NY 1991, p. 1209-1211.
J. Fry et al. J Org. Chem. 1978, 43, 374.
J. Kaiser et al. Microbiol. Rev. 1966, 60(3), 483.
J. Sauter et al. JACS 1959, 81, 3881.
J. Sauter et al., JACS 1959, 81, 3677.
J. Vekemans et al. J. Org. Chem. 1990, 55, 5336.
J.A. Boogers et al. Org. Process &Develop. 2007, 11, 585.
J.A. Murphy et al. Org. Letters 2005, 7, 1427.
J.Beger J. Prakt. Chem. 1991, 333, 677.
J.E. Bordwell at al. J. Org. Chem. 1963, 28, 1765.
J.M.Holland et al. J. Org. Chem. 2003, 68, 747.
J.Nui et al. JACS 2009, 74,5075.
K. Guthikonda et al. 2002, 124, 13672.
K. Haffner et al. Tetrahedron Letters 1964, 52, 3953.
K. Kageyama et al. J. Org Chem. 1975, 40, 1932.
K.B. Lindday et al. J. Org. Chem. 2006, 71, 4766.
K.Purushothoma et al. Synlett 2000, 5, 683.
M. Inoue et al. J. Heterocycl. Chem. 1984, 21, 725.
M. Kim et al. Archiv of Pharm. Res. 2004, 27, 151.
M. Maier et al. Synlett 1995, 1029.
M. Shah et al. Tetrahedron Letters 1986, 27, 5437.
M.Bohdansky,Princelpes of Peptide Synthesis, Springer Verlag, Berlin 1984.
M.E. Tanner et al. Tetrahedron lett. 1994, 35, 4073.
M.E.Mayer et al. Liebigs Ann. Chem. 1990, 323.
M.Kawamura et al. Tetrahedron 2006, 62, 9201.
M.T. Barros et al. Tetrahedron 2009, 65, 396.
M.Yato et al. Heterocycles 1998, 49, 233.
N.Bensel et al. Tetrahedron Lett. 2002,43,4281.
N.J. Manesis et al. J. Org. Chem. 1987, 52, 5331.
N.S.Zefirov et al. J. Org. Chem. 1982, 47, 3679.
P. Herold et al. J. Org. Chem. 1989, 54, 1178.
P.A. Evans et al. Tetrahedron Letters 1997, 38, 5249.
P.A. Evans et al. Tetrahedron Letters 1999, 40, 1253.
P.A. Wehrli J. Org. Chem. 1977, 42, 2939.
R. Chenevert et al. J. Org. Chem. 1996, 61, 1219.
R. Goschke et al. Helv. Chim. Acta 2003, 86, 2848.
S. Behr et al. Eur. J. Org Chem. 2004, 3884.
S. Fiaravanti et al. J. Org. Chem. 2005, 70, 3296.
S. Henessian et al. J. Org. Chem. 2002, 67, 4261.
S. Henessian et al. Org. Lett. 2010, 12, 1816.
S. Nahm et al. Tetrahedron Letters 1981, 22, 3815.
S. Repichet et al. Tetrahedron Letters, 2003, 44, 2037.
S.Gowrisankar et al. JACS 2010, 132,11592.
T. Sugiyama Bull. Inst. Chem. Res. Kyoto Univ. 1989, 67, 112.
T.J. Donohoe et al. Org. Lett. 2009, 11, 2305.
TCI Reagent Gude 2009-2010, 50-66 16-17 85-89 90-93.
W. Greene et al. Protective Groups in org. Synthesis, 3rd Ed. J. Wiley&Sons 1999, p. 17-245, 494-653.
W.W.Zajac et al. J. Org. Chem. 1986, 51, 2617.
Y. Goldberg et al. tetrahedron 1990, 46, 1911.

Also Published As

Publication number Publication date
US20120296100A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
US9174958B2 (en) Process for the preparation of dronedarone
JP5208239B2 (en) Novel production method of anticancer active tricyclic compounds by alkyne coupling
JP2015083570A (en) Intermediate for synthesis of benzoindene prostaglandin and manufacturing method therefor
JP5873484B2 (en) Dronedarone and method for producing the salt thereof
US8614337B2 (en) S-5-substituent-N-2′-(thiophene-2-yl)ethyl-tetralin-2-amine or chiral acid salts thereof and use for preparing Rotigotine
US20110237832A1 (en) Synthesis of hdac inhibitors: trichostatin a and analogues
CN105061230A (en) Method for preparing dapoxetine hydrochloride
Li et al. An efficient enantioselective synthesis of florfenicol via a vanadium-catalyzed asymmetric epoxidation
US8703976B2 (en) Manufacturing process for 8-aryloctanoic acids such as Aliskiren
US20120071673A1 (en) Synthesis of (s)-n-[2-(1,6,7,8-tetrahydro-2h-indeno-[5,4-b]furan-8-yl)ethyl]propionamide
CN103288768B (en) Asymmetric synthetic method of optical pure amorolfine hydrochloride
JP2022055368A (en) Method for producing benzoazepine derivative and intermediate thereof
JP4286524B2 (en) A method for producing 4-alkoxyphenyl-4-oxo-butyric acid and a method for producing 7-alkoxy-1-tetralones.
TWI500596B (en) Method for synthesizing 3,4-dimethoxybicyclo[4.2.0]oct-1,3,5-triene-7-carbonitrile, and synthesis of ivabradine (IVABRADINE) and its Acceptable acid addition salt application
US6403814B1 (en) Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
EP2730562A1 (en) Novel method for synthesising (2E)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid
CA2835459C (en) New process for synthesizing 3-(2-bromo-4,5-dimethoxyphenyl) propanenitrile, and application in the synthesis of ivabradine and its addition salts to a pharmaceutically acceptableacid.
JP2021127332A (en) Method for Producing 5-Bromo-2-alkylbenzoic Acid
JP5837114B2 (en) (7S) -3,4-Dimethoxybicyclo [4.2.0] enzymatic synthesis method of octa-1,3,5-triene-7-carboxylic acid and application in the synthesis of ivabradine and its salts
WO2005021465A1 (en) Method for producing aromatic unsaturated compound
CN102648192B (en) Preparation method of 1,2,6,7-tetrahydro-8H-indeno[5,4-B]furan-8-one
JPH07103098B2 (en) Efficient Stereoconservative Synthesis of 1-Substituted (S)-and (R) -2-Aminomethylpyrrolidines and Intermediates Thereof
KR100914849B1 (en) The method for preparation of 2-sulfonyloxy-1-(4-hydroxyphenyl)ethanol derivatives
CN103183604A (en) Preparation method of vedaprofen
JP4937442B2 (en) Process for producing 5-fluorooxindole

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180422